Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
BRAINSTORM CELL THERAPEUTICS LTD. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is being reviewed by 1 distinct examiner within 1 distinct art unit. Such a focused portfolio allows for a direct line of communication with the examining staff. For the practitioner, this concentration means that the prosecution of the company's biotechnology interests is currently centered on a single point of contact at the patent office.
ABUZEINEH, HANAN ISAM is the busiest examiner for this portfolio, with 1 pending office action currently assigned. Since there is only 1 distinct examiner involved, this examiner manages all current office action activity for the company. This alignment between the examiner and the 1 distinct art unit provides a singular point of contact for the pending matter. The presence of 1 pending office action indicates a highly specific prosecution phase. Practitioners can dedicate their efforts to the specific requirements of ABUZEINEH, HANAN ISAM, ensuring that the response to the pending office action is tailored to the examiner's established patterns within the pharmaceutical sector.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ABUZEINEH, HANAN ISAM | 1 | 51.9% | +54.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18576102 | METHODS OF GENERATING MESENCHYAL STEM CELLS WHICH SECRETE NEUROTROPHIC FACTORS IN A BIOREACTOR SYSTEM | ABUZEINEH, HANAN ISAM | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18576102 | METHODS OF GENERATING MESENCHYAL STEM CELLS WHICH SECRETE NEUROTROPHIC FACTORS IN A BIOREACTOR SYSTEM | ABUZEINEH, HANAN ISAM | — |
| Art Unit | Apps |
|---|---|
| 1633 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18576102 | METHODS OF GENERATING MESENCHYAL STEM CELLS WHICH SECRETE NEUROTROPHIC FACTORS IN A BIOREACTOR SYSTEM | ABUZEINEH, HANAN ISAM | 1633 | §102§103§112 | Non-Final OA | — | Pending | Jan 03, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBRAINSTORM CELL THERAPEUTICS LTD. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Hanan Isam Abuzeineh has the most, with 1 of BRAINSTORM CELL THERAPEUTICS LTD.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
